Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F003 - Treating Tumors and Inflammatory Skin Diseases with Immunomodulators and Biologics

Friday, February 16; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Categorize and differentiate dermatoses based on their inflammatory versus neoplastic origin and their potential responses to topical and systemic immunotherapies.
  • Recognize potential applications of immune-based therapies outside of conventional uses.
  • Select therapeutic options to modify a disease process in addition to alleviate symptoms based on the immune mechanisms that create them.


As the understanding of the immune system pathways continues to expand, so must the
potential applications of immunomodulators that can impact the process of diseases instead
 of just symptoms. Our current therapeutic regimens are as efficacious as our comfort with their mechanisms of action. This begins with matching appropriate immune processes as “building blocks” of diseases to those counteracted and modified by the therapies. The goals of this session are to dissect various immune system functions that create inflammatory dermatoses and facilitate neoplasia, and explore applications of topical and systemic therapies that could potentially serve as standards of care


  • Cowen, Edward W., MD: Elsevier Inc. – O(OB); UpToDate, Inc – O(OB);
  • Friedman, Adam J., MD: AbbVie – Speaker/Faculty Education(H); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Allergan, Inc. – Speaker/Faculty Education(H); Amgen – A(H), Speaker/Faculty Education(H); Bayer – SP(H); Biogen – A(H); Dermira – C(H); Eli Lilly and Company – C(H); Encore Dermatology, Inc. – C(H); Exeltis – C(H); Galderma USA – C(H); Hoth Therapeutics – A(H); IntraDerm Pharmaceuticals – C(H); Janssen Biotech – SP(H), Speaker/Faculty Education(H); Johnson and Johnson Consumer Products Company – C(H); La Roche-Posay Laboratorie Pharmaceutique – A(H), C(H); Medscape – Speaker/Faculty Education(H); Menlo Therapeutics – A(H); Novartis – A(H); Oculus innovative Sciences, Inc. – C(H); Orlando Dermatology Aesthetic & Clinical (ODAC) – SP(H); Ortho Dermatologics – A(H); Pfizer Inc. – C(H); Promius Pharma, LLC – A(H), SP(H); Regeneron – Speaker/Faculty Education(H); Sanova Works – C(H); Valeant Pharmaceuticals International – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – A(H);
  • Han, George, MD, PhD: Celgene – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); MC2 Therapeutics – I(Grants/Research Funding); Pfizer Inc. – SP(H); Regeneron Pharmaceuticals, Inc. – A(H), SP(H); Sanofi – A(H), SP(H); Sonoma Pharmaceuticals – A(H); Sun Pharmaceutical Industries Ltd. – SP(H);
  • Harris, John, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – C(Fees); BiologicsMD, Inc. – C(H); Celgene Corporation – I(Grants/Research Funding); Combe Incorporated – C(Fees); Concert Pharmaceuticals – A(H); Dermavant Sciences – C(Fees), I(Grants/Research Funding); Dermira – I(Grants/Research Funding); EMD Serono – C(H); Genzyme Corporation – C(H), I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – C(H); Leo Pharma Inc – I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novartis – C(Fees); Pfizer Inc. – C(H), I(Grants/Research Funding); Rheos Medicines – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); TeVido Biodevices, LLC – A(SO), I(Grants/Research Funding), SH(ST); Third Rock Ventures – A(H); Villaris Therapeutics, Inc – F(ST), I(Grants/Research Funding);
  • Venna, Suraj S., MD: no financial relationships exist with commercial interests.
  • Zippin, Jonathan, MD, PhD: Celgene – C(Fees), I(Grants/Research Funding); CEP Biotech – F(ST); Medimetriks Pharmaceuticals, Inc. – C(Fees); Pfizer Inc. – I(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – E(S); Shade, Inc – A(SO);
Friday, February 16
9:00 AM
Dr. Han / Off Label Uses for Immunomodulators and Biologics
9:18 AM
Dr. Han / Q&A
9:20 AM
Dr. Cowen / Auto inflammatory Diseases: Potential for Immunotherapy
9:38 AM
Dr. Cowen / Q&A
9:40 AM
Dr. Harris / Targeted immunotherapy for vitiligo and alopecia areata
9:58 AM
Dr. Harris / Q&A
10:00 AM
Dr. Zippin / Targeting cAMP Signaling for the Treatment of Inflammatory Diseases of the Skin
10:18 AM
Dr. Zippin / Q&A
10:20 AM
Dr. Venna / Immunotherapy for Melanoma
10:38 AM
Dr. Venna / Q&A
10:40 AM
Dr. Friedman / The Potential of Cannabinoids for the Treatment of Inflammatory and Neoplastic Diseases of the Skin
10:58 AM
Dr. Friedman / Q&A
Event Details
  • Date
    Friday, February 16
  • Time
    9:00 AM - 11:00 AM
  • Location
    Ballroom 20A
  • CME Credits
  • Type
  • Adam J. Friedman, MD, FAAD - Handout
  • George Han, MD, PhD, FAAD
  • Edward W. Cowen, MD, FAAD
  • John Harris, MD, PhD, FAAD
  • Jonathan Zippin, MD, PhD, FAAD
  • Suraj S. Venna, MD, FAAD